2022 World Conference on Lung Cancer (ePosters)-EP08.01-017. Evaluation of Blood Tumor Mutation Burden for Efficacy of Second- Line Atezolizumab Treatment in Non-small Cell Lung Cancer

EP08.01-017. Evaluation of Blood Tumor Mutation Burden for Efficacy of Second- Line Atezolizumab Treatment in Non-small Cell Lung Cancer

Back to course

Pdf Summary

This study aimed to evaluate the feasibility of using blood tumor mutation burden (bTMB) as a biomarker for the efficacy of atezolizumab treatment in previously treated patients with non-small cell lung cancer (NSCLC). The study analyzed the characteristics of patients and their response to treatment.<br /><br />The results showed that there was no significant difference in overall response rate (ORR) according to bTMB. There was also no correlation between bTMB and circulating cell-free DNA (cfDNA) concentration. However, there were more prominent changes in bTMB from baseline to cycle 4 in patients with durable clinical benefit (DCB) compared to those with non-durable clinical benefit (NCB).<br /><br />The study also found that patients with low cfDNA concentration at baseline had longer progression-free survival (PFS) compared to those with high cfDNA concentration. There was also a significant PFS benefit in the subgroup of patients with low cfDNA concentration and high PD-L1 expression.<br /><br />Additionally, the study found that TP53 mutation was the most common mutation, but there was no significant difference in PFS based on TP53 mutation status. The study also analyzed other mutation profiles and found differences between DCB and NCB in genes such as KRAS, NF1, PIK3CA, JAK2, NFE2L2, and RB1.<br /><br />In conclusion, the study suggests that bTMB may not be a reliable biomarker for the efficacy of atezolizumab treatment in previously treated NSCLC patients. However, the analysis of cfDNA concentration, mutation profiling, and PD-L1 expression could assist in selecting patients who would benefit the most from immune checkpoint inhibitor treatment. Further research is needed to validate these findings.

Asset Subtitle

Cheol-Kyu Park

Meta Tag

Speaker Cheol-Kyu Park

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

blood tumor mutation burden

atezolizumab treatment

non-small cell lung cancer

cfDNA concentration

progression-free survival

PD-L1 expression

TP53 mutation

KRAS

NF1

immune checkpoint inhibitor treatment